Furthermore, injecting insulin containing aggregates or fibrils can contribute to injection-site complications, including lipohypertrophy, lipoatrophy, and insulin-derived amyloidosis, while also impairing glycemic control [22]. This evidence concerns the gene INS and amyloidosis.